Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 14,460	$ 7,445
General and administrative	8,927	3,336
Total operating expenses	23,387	10,781
Loss from operations	(23,387)	(10,781)
Grant income	2,234	1,831
Other income, net	173	84
Net loss	(20,980)	(8,866)
Unrealized loss on available-for-sale securities	(1,068)	(5)
Comprehensive loss attributable to common stockholders	$ (22,048)	$ (8,871)
Net loss per share attributable to common stockholders, basic and diluted	$ (0.56)	$ (0.25)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted	37,593,328	35,775,454